Abbott Laboratories (ABT)
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Abbott Laboratories' NYSE: ABT October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat data include increasing coverage with newly initiated ratings appearing within days of the Q3 earnings release.
Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth
The Goldman Sachs Conviction List is a curated list of stocks that the firm's research team believes have a high likelihood of outperforming the market.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Joanne Wuensch - Citigroup Inc., Research Division Travis Steed - BofA Securities, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Good morning, and thank you for standing by.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings
Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview)
Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. Abbott's Q2 results showed strong earnings growth, but the stock fell due to expectations of a bigger beat. The company is building a defensible position in the diabetes ecosystem, moving beyond devices to data-driven, integrated care solutions.
Abbott (ABT) Laps the Stock Market: Here's Why
Abbott (ABT) reached $134.59 at the closing of the latest trading day, reflecting a +1.2% change compared to its last close.
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.
Best Dividend Aristocrats For October 2025
Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristocrats already raising payouts in 2025 at an average rate of 5.19%, nearing last year's pace. 22 Dividend Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
